Humacyte shares jumped 12% pre-market after the FY2026 Department of Defense (DOD) Appropriations Act included funding for its bioengineered blood vessels. The funding supports evaluating Symvess for warfighters with traumatic injuries. Symvess is the only FDA-approved human-derived bioengineered blood vessel. Retail sentiment remains bearish despite the surge.